- Home
- AKBA vs BJRI Comparison
AKBA vs BJRI Comparison
Compare AKBA & BJRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- BJRI
- Stock Information
- Founded
- AKBA 2007
- BJRI 1978
- Country
- AKBA United States
- BJRI United States
- Employees
- AKBA N/A
- BJRI N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- BJRI Restaurants
- Sector
- AKBA Health Care
- BJRI Consumer Discretionary
- Exchange
- AKBA Nasdaq
- BJRI Nasdaq
- Market Cap
- AKBA 729.1M
- BJRI 706.6M
- IPO Year
- AKBA 2014
- BJRI 1996
- Fundamental
- Price
- AKBA $3.09
- BJRI $30.92
- Analyst Decision
- AKBA Strong Buy
- BJRI Hold
- Analyst Count
- AKBA 5
- BJRI 6
- Target Price
- AKBA $6.90
- BJRI $38.67
- AVG Volume (30 Days)
- AKBA 2.6M
- BJRI 449.4K
- Earning Date
- AKBA 11-06-2025
- BJRI 10-30-2025
- Dividend Yield
- AKBA N/A
- BJRI N/A
- EPS Growth
- AKBA N/A
- BJRI N/A
- EPS
- AKBA N/A
- BJRI 1.17
- Revenue
- AKBA $203,733,000.00
- BJRI $1,383,611,000.00
- Revenue This Year
- AKBA $43.91
- BJRI $5.21
- Revenue Next Year
- AKBA $32.09
- BJRI $2.87
- P/E Ratio
- AKBA N/A
- BJRI $26.90
- Revenue Growth
- AKBA 16.75
- BJRI 4.07
- 52 Week Low
- AKBA $1.52
- BJRI $28.92
- 52 Week High
- AKBA $4.08
- BJRI $47.02
- Technical
- Relative Strength Index (RSI)
- AKBA 59.78
- BJRI 48.11
- Support Level
- AKBA $2.93
- BJRI $30.43
- Resistance Level
- AKBA $3.19
- BJRI $32.86
- Average True Range (ATR)
- AKBA 0.13
- BJRI 1.12
- MACD
- AKBA 0.04
- BJRI 0.24
- Stochastic Oscillator
- AKBA 91.92
- BJRI 54.02
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.